Kyverna Therapeutics Reports Q3 2025 Financial Results with Increased Losses and Cash Decrease

Kyverna Therapeutics, Inc. reported significant financial results for the third quarter and the first nine months of 2025, revealing a net loss of $36.8 million for the quarter and $123.5 million for the nine-month period, compared to losses of $34.5 million and $90.0 million, respectively, in the same periods of 2024. The company's total operating expenses for the third quarter were $38.7 million, slightly down from $38.8 million a year earlier, while expenses for the nine months increased by 29% to $130.5 million, driven primarily by a 31% rise in research and development costs, which reached $103.7 million.

Kyverna's cash and cash equivalents, along with available-for-sale marketable securities, totaled $171.1 million as of September 30, 2025, a decrease from $290.6 million at the end of 2024. The decline in cash reserves is attributed to ongoing operational losses and increased spending on clinical development, particularly for its lead product candidate, KYV-101, which is in late-stage clinical trials for autoimmune diseases. The company has also reported an accumulated deficit of $387.0 million as of the end of the third quarter.

In terms of operational developments, Kyverna has made strides in its clinical pipeline, particularly with KYV-101, which is being evaluated in registrational trials for stiff person syndrome and generalized myasthenia gravis. The company completed patient enrollment for the Phase 2 trial in stiff person syndrome in the second quarter of 2025 and expects to report top-line data in early 2026. Additionally, interim data from the Phase 2 portion of the registrational trial for generalized myasthenia gravis was presented at a recent medical conference, with plans to initiate the Phase 3 portion by the end of 2025.

Strategically, Kyverna has entered into a Loan and Security Agreement with Oxford Finance, providing a term loan facility of up to $150 million, with an initial tranche of $40 million drawn in November 2025. This funding is expected to support the company's operations and clinical development plans through at least 2027. The company continues to explore additional financing options, including equity and debt offerings, to sustain its operations and advance its product candidates.

Looking ahead, Kyverna anticipates continued operational losses as it invests in the development of its product candidates and expands its clinical trials. The company remains focused on achieving regulatory approvals and commercializing its therapies, although it acknowledges the inherent risks and uncertainties associated with drug development. The management has indicated that the current cash reserves, along with the new financing, should be sufficient to fund operations for the foreseeable future, but additional capital may be necessary to support ongoing and future initiatives.